Effect of gifitinib combined with hydroxylcamptothecin pericardial perfusion in the treatment of advanced non-small cell lung cancer with pericardial effusion
10.3760/cma.j.issn.1008-6706.2019.08.018
- VernacularTitle:羟基喜树碱心包灌注联合吉非替尼治疗晚期非小细胞肺癌伴心包积液的效果观察
- Author:
Jingbao ZHANG
1
;
Yanfei GAO
Author Information
1. 山东省
- Keywords:
Gefitinib;
Hydroxycamptothecine;
Drug therapy,combination;
Chemotherapy,cancer,regional perfusion;
Carcinoma,non-small-cell lung;
Pericardial effusion;
Treatment outcome;
Controlled clini-cal trial
- From:
Chinese Journal of Primary Medicine and Pharmacy
2019;26(8):968-971
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical effect of gifitinib combined with hydroxylcamptothecin pericardial perfusion in the treatment of patients with advanced non-small cell lung cancer(NSCLC) with pericardial effusion. Methods From January 2016 to September 2017,eighty-four cases of late NSCLC with pericardial effusion treated in the People′s Hospital of Jiaozhou were randomly divided into two groups according to the digital table,with 42 cases in each group.The control group was treated with gefitinib,and the observation group was treated with hydroxylcampto-thecin on the basis of the control group.The curative effect was evaluated after two courses of treatment in the two groups,and the clinical efficacy and adverse reactions were observed.Results The effective rates of the control group and the observation group were 47.6% (20/42) and 66.7% (28/42),respectively.The effective rate of the observa-tion group was significantly higher than that of the control group(χ2 =4.525,P<0.05).The effective rate of pericar-dial effusion was 33.3% (14/42) in the control group and 69.1% (29/42) in the observation group,the difference between the two groups was statistically significant( χ2 =10.720,P <0.05).There was no ststistically significant difference in the incidence rate of adverse reactions between the two groups during treatment(P<0.05).Conclusion Combination of gefitinib and hydroxylcamptothecin pericardial perfusion in the treatment of NSCLC with pericardial effusion has good tolerance and good safety for the patients.
